TY - JOUR T1 - Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy JF - Saudi Medical Journal JO - Saudi Med J SP - 213 LP - 217 DO - 10.15537/smj.2022.43.2.20210736 VL - 43 IS - 2 AU - Mohammed AlSheef AU - Ghaydaa Kullab AU - Modhi Alajmi AU - Ruba Aldhaheri AU - Sultan Al Baqmi AU - Haya Alajlan AU - Abdul Rehman Z. Zaidi AU - Amani Abu-Shaheen Y1 - 2022/02/01 UR - http://smj.org.sa/content/43/2/213.abstract N2 - Objectives: To share clinical data on the efficacy of 4F-PCC in the treatment of major bleeding caused by warfarin, dabigatran, and rivaroxaban.Methods: This is a retrospective study of patients admitted to King Fahad Medical City, Riyadh, Saudi Arabia with major bleeding caused by oral anticoagulants and treated with 4-factor prothrombin complex concentrate (4F-PCC). The International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria were used to evaluate the effectiveness of PCCs.Results: A total of 22 patients were included in the study. Ten of the events were caused by gastrointestinal bleeding (46%). In the majority of patients, anticoagulation was prescribed for stroke prevention, atrial fibrillation, and venous thromboembolism. The median international normalized ratio was significantly lower before and after PCC administration (p<0.001). In patients treated with 4-factor PCC, the rate of thromboembolic events was 0%. The hemostatic effectiveness of PCC was effective in 19 patients. During treatment, no clinically significant bleeding complications occurred.Conclusion: Prothrombin complex concentrate can effectively reverse the effects of warfarin and rivaroxaban in patients with major bleeding, but only partially reverses the effect of dabigatran. ER -